Suppr超能文献

多糖硫酸化寡糖糖苷的合成及作为血管生成和肿瘤生长抑制剂的生物评价。

Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.

机构信息

Drug Design Group, Progen Pharmaceuticals Limited, Toowong, Queensland 4066, Australia.

出版信息

J Med Chem. 2010 Feb 25;53(4):1686-99. doi: 10.1021/jm901449m.

Abstract

A series of polysulfated penta- and tetrasaccharide glycosides containing alpha(1-->3)/alpha(1-->2)-linked mannose residues were synthesized as heparan sulfate (HS) mimetics and evaluated for their ability to inhibit angiogenesis. The compounds bound tightly to angiogenic growth factors (FGF-1, FGF-2, and VEGF) and strongly inhibited heparanase activity. In addition, the compounds exhibited potent activity in cell-based and ex vivo assays indicative of angiogenesis, with tetrasaccharides exhibiting activity comparable to that of pentasaccharides. Selected compounds also showed good antitumor activity in vivo in a mouse melanoma (solid tumor) model resistant to the phase III HS mimetic 1 (muparfostat, formerly known as PI-88). The lipophilic modifications also resulted in reduced anticoagulant activity, a common side effect of HS mimetics, and conferred a reasonable pharmacokinetic profile in the rat, as exemplified by the sulfated octyl tetrasaccharide 5. The data support the further investigation of this class of compounds as potential antiangiogenic, anticancer therapeutics.

摘要

一系列含有α(1--->3)/α(1--->2)-连接的甘露糖残基的多硫酸化五糖和四糖糖苷被合成为硫酸乙酰肝素 (HS) 类似物,并评估其抑制血管生成的能力。这些化合物与血管生成生长因子 (FGF-1、FGF-2 和 VEGF) 紧密结合,并强烈抑制肝素酶活性。此外,这些化合物在基于细胞的和离体检测中表现出很强的血管生成活性,四糖表现出与五糖相当的活性。选定的化合物在体内对耐 III 期 HS 类似物 1(muparfostat,以前称为 PI-88)的小鼠黑色素瘤(实体瘤)模型中也表现出良好的抗肿瘤活性。亲脂性修饰还降低了抗凝血活性,这是 HS 类似物的常见副作用,并在大鼠中赋予了合理的药代动力学特征,以硫酸辛基四糖 5 为例。这些数据支持进一步研究这类化合物作为潜在的抗血管生成、抗癌治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验